Search

Your search keyword '"Wendel, L."' showing total 18 results
Start Over Author "Wendel, L." Publication Type Electronic Resources
18 results on '"Wendel, L."'

1. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

Author

Piñana, J.L., Tridello, G., Xhaard, A., Wendel, L., Montoro, J., Vazquez, L., Heras, I., Ljungman, P., Mikulska, M., Salmenniemi, U., Perez, A., Kröger, N., Cornelissen, J, Sala, E., Martino, R., Geurten, C., Byrne, J., Maertens, J., Kerre, T., Martin, M, Pascual, M.J., Yeshurun, M., Finke, J., Groll, A.H., Shaw, P.J., Blijlevens, N.M.A., Arcese, W., Ganser, A., Suarez-Lledo, M., Alzahrani, M., Choi, G., Forcade, E., Paviglianiti, A., Solano, C., Wachowiak, J., Zuckerman, T., Bader, P., Clausen, J., Mayer, J., Schroyens, W., Metafuni, E., Knelange, N., Averbuch, D., Camara, R. de la, Piñana, J.L., Tridello, G., Xhaard, A., Wendel, L., Montoro, J., Vazquez, L., Heras, I., Ljungman, P., Mikulska, M., Salmenniemi, U., Perez, A., Kröger, N., Cornelissen, J, Sala, E., Martino, R., Geurten, C., Byrne, J., Maertens, J., Kerre, T., Martin, M, Pascual, M.J., Yeshurun, M., Finke, J., Groll, A.H., Shaw, P.J., Blijlevens, N.M.A., Arcese, W., Ganser, A., Suarez-Lledo, M., Alzahrani, M., Choi, G., Forcade, E., Paviglianiti, A., Solano, C., Wachowiak, J., Zuckerman, T., Bader, P., Clausen, J., Mayer, J., Schroyens, W., Metafuni, E., Knelange, N., Averbuch, D., and Camara, R. de la

Abstract

Contains fulltext : 304925.pdf (Publisher’s version ) (Closed access), BACKGROUND: Human metapneumovirus (hMPV) epidemiology, clinical characteristics and risk factors for poor outcome after allogeneic stem cell transplantation (allo-HCT) remain a poorly investigated area. METHODS: This retrospective multicenter cohort study examined the epidemiology, clinical characteristics, and risk factors for poor outcomes associated with human metapneumovirus (hMPV) infections in recipients of allo-HCT. RESULTS: We included 428 allo-HCT recipients who developed 438 hMPV infection episodes between January 2012 and January 2019. Most recipients were adults (93%). hMPV infections were diagnosed at a median of 373 days after allo-HCT. The infections were categorized as upper respiratory tract disease (URTD) or lower respiratory tract disease (LRTD), with 60% and 40% of cases, respectively. Patients with hMPV LRTD experienced the infection earlier in the transplant course and had higher rates of lymphopenia, neutropenia, corticosteroid use, and ribavirin therapy. Multivariate analysis identified lymphopenia and corticosteroid use (>30 mg/d) as independent risk factors for LRTD occurrence. The overall mortality at day 30 after hMPV detection was 2% for URTD, 12% for possible LRTD, and 21% for proven LRTD. Lymphopenia was the only independent risk factor associated with day 30 mortality in LRTD cases. CONCLUSIONS: These findings highlight the significance of lymphopenia and corticosteroid use in the development and severity of hMPV infections after allo-HCT, with lymphopenia being a predictor of higher mortality in LRTD cases.

Published
2024

2. Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.

Author

Styczynski, J., Tridello, G., Koster, L, Knelange, N., Wendel, L., Biezen, A. van, Werf, S. van der, Mikulska, M., Gil, L., Cordonnier, C., Ljungman, P., Averbuch, D., Cesaro, S., Baldomero, H., Chabannon, C., Corbacioglu, S., Dolstra, H., Glass, B., Greco, R., Kröger, N., Latour, R.P. de, Mohty, M., Neven, B., Peric, Z., Snowden, J.A., Sureda, A., Yakoub-Agha, I., Camara, R. de la, Styczynski, J., Tridello, G., Koster, L, Knelange, N., Wendel, L., Biezen, A. van, Werf, S. van der, Mikulska, M., Gil, L., Cordonnier, C., Ljungman, P., Averbuch, D., Cesaro, S., Baldomero, H., Chabannon, C., Corbacioglu, S., Dolstra, H., Glass, B., Greco, R., Kröger, N., Latour, R.P. de, Mohty, M., Neven, B., Peric, Z., Snowden, J.A., Sureda, A., Yakoub-Agha, I., and Camara, R. de la

Abstract

01 augustus 2023, Item does not contain fulltext, We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence and specific causes of death after HCT, with focus on infectious deaths in two time periods, 1980-2001 (cohort-1) and 2002-2015 (cohort-2). All patients with HCT for lymphoma, plasma cell disorders, chronic leukemia (except CML), myelodysplastic/myeloproliferative disorders, registered in the EBMT-ProMISe-database were included (n = 232,618) (COD-2 study). Results were compared to those in the ALL/AML/CML COD-1 study. Mortality from bacterial, viral, fungal, and parasitic infections decreased in very early, early and intermediate phases. In the late phase, mortality from bacterial infections increased, while mortality from fungal, viral, or unknown infectious etiology did not change. This pattern was similar for allo- and auto-HCT in COD-1 and COD-2 studies, with a distinct and constant lower incidence of all types of infections at all phases, after auto-HCT. In conclusion, infections were the main cause of death before day +100, followed by relapse. Mortality from infectious deaths significantly decreased, except late phase. Post-transplant mortality has significantly decreased in all phases, from all causes after auto-HCT; it has decreased in all phases after allo-HCT except late phase.

Published
2023

3. Roadmap for optical tweezers

Author

Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A.R., Moreira, Wendel L., Fontes, Adriana, Cesar, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F.D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, García, Laura Pérez, Arzola, Alejandro V., Castillo, Isaac Pérez, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Marmolejo, Javier Tello, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Felix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Ciriza, David Bronte, Iatì, Maria Antonia, Swartzlander, Grover A., Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A.R., Moreira, Wendel L., Fontes, Adriana, Cesar, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F.D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, García, Laura Pérez, Arzola, Alejandro V., Castillo, Isaac Pérez, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Marmolejo, Javier Tello, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Felix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Ciriza, David Bronte, Iatì, Maria Antonia, and Swartzlander, Grover A.

Abstract

Optical tweezers are tools made of light that enable contactless pushing, trapping, and manipulation of objects, ranging from atoms to space light sails. Since the pioneering work by Arthur Ashkin in the 1970s, optical tweezers have evolved into sophisticated instruments and have been employed in a broad range of applications in the life sciences, physics, and engineering. These include accurate force and torque measurement at the femtonewton level, microrheology of complex fluids, single micro- and nano-particle spectroscopy, single-cell analysis, and statistical-physics experiments. This roadmap provides insights into current investigations involving optical forces and optical tweezers from their theoretical foundations to designs and setups. It also offers perspectives for applications to a wide range of research fields, from biophysics to space exploration.

Published
2023

4. Roadmap for optical tweezers

Author

Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A.R., Moreira, Wendel L., Fontes, Adriana, Cesar, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F.D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, García, Laura Pérez, Arzola, Alejandro V., Castillo, Isaac Pérez, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Marmolejo, Javier Tello, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Felix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Ciriza, David Bronte, Iatì, Maria Antonia, Swartzlander, Grover A., Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A.R., Moreira, Wendel L., Fontes, Adriana, Cesar, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F.D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, García, Laura Pérez, Arzola, Alejandro V., Castillo, Isaac Pérez, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Marmolejo, Javier Tello, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Felix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Ciriza, David Bronte, Iatì, Maria Antonia, and Swartzlander, Grover A.

Abstract

Optical tweezers are tools made of light that enable contactless pushing, trapping, and manipulation of objects, ranging from atoms to space light sails. Since the pioneering work by Arthur Ashkin in the 1970s, optical tweezers have evolved into sophisticated instruments and have been employed in a broad range of applications in the life sciences, physics, and engineering. These include accurate force and torque measurement at the femtonewton level, microrheology of complex fluids, single micro- and nano-particle spectroscopy, single-cell analysis, and statistical-physics experiments. This roadmap provides insights into current investigations involving optical forces and optical tweezers from their theoretical foundations to designs and setups. It also offers perspectives for applications to a wide range of research fields, from biophysics to space exploration.

Published
2023

5. Roadmap for optical tweezers

Author

NASA Innovative Advanced Concepts, Australian Research Council, Japan Society for the Promotion of Science, Boğaziçi Üniversity, Novo Nordisk UK Research Foundation, Knut and Alice Wallenberg Foundation, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Universidad Autónoma de Madrid, Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasil), Universidade Federal do Ceará, Agenzia Spaziale Italiana, Istituto Nazionale di Astrofisica, Agence Nationale de la Recherche (France), Wellcome Trust, Austrian Science Fund, Universidad Nacional Autónoma de México, European Commission, European Research Council, German Research Foundation, Natural Sciences and Engineering Research Council of Canada, Swedish Research Council, Engineering and Physical Sciences Research Council (UK), Office of Naval Research (US), National Science Foundation (US), Institute of Geology of the Czech Academy of Sciences, Czech Science Foundation, Generalitat de Catalunya, University of Münster, Department of Science and Technology (India), Human Frontier Science Program, Biotechnology and Biological Sciences Research Council (UK), Medical Research Council (UK), Danish National Research Foundation, Independent Research Fund Denmark, Beckman Institute, Associazione Italiana per la Ricerca sul Cancro, Volpe, Giovanni [0000-0001-5057-1846], Maragò, Onofrio M. [0000-0002-7220-8527], Rubinsztein-Dunlop, Halina [0000-0002-8332-2309], Stilgoe, Alexander B. [0000-0002-9299-5695], Volpe, Giorgio [0000-0001-9993-5348], Truong, Viet Giang [0000-0003-3589-7850], Chormaic, Síle Nic [0000-0003-4276-2014], Elahi, Parviz [0000-0003-3545-8436], Käll, Mikael [0000-0002-1163-0345], Callegari, Agnese [0000-0002-4488-4106], Neves, Antonio A. R. [0000-0002-2615-8573], Eismann, Jörg S. [0000-0002-2495-4613], Banzer, Peter [0000-0002-6336-6953], Roy, Basudev [0000-0003-0737-2889], Thalhammer-Thurner, Gregor [0000-0002-3948-8045], Ritsch-Marte, Monika [0000-0002-5945-546X], Pérez Castillo, Isaac0000-0001-7622-9440, Muenker, Till M. [0000-0003-3225-8746], Vos, Bart E. [0000-0002-4325-6298], Betz, Timo [0000-0002-1548-0655], Reece, Peter J. [0000-0003-4852-3735], McGloin, David [0000-0002-0075-4481], Gordon, Reuven [0000-0002-1485-6067], Bruce, Graham D. [0000-0003-3403-0614], Dholakia, Kishan [0000-0001-6534-9009], Roichman, Yael [0000-0003-1927-4506], Bobkova, Valeriia [0000-0003-4080-9069], Wittkowski, Raphael [0000-0003-4881-9173], Denz, Cornelia [0000-0002-7292-2499], Pavan Kumar, G. V. [0000-0002-4036-7187], Foti, Antonino [0000-0002-9824-3099], Donato, Maria Grazia [0000-0002-7580-3137], Gucciardi, Pietro G. [0000-0003-1826-9174], Gardini, Lucia [0000-0003-0923-9221], Kashchuk, Anatolii V. [0000-0002-2364-9393], Capitanio, Marco [0000-0002-9799-9353], Paterson, Lynn [0000-0003-0493-5041], Jones, Philip H. [0000-0002-0860-631X], Berg-Sørensen, Kirstine [0000-0002-9977-3980], Oddershede, Lene B. [0000-0003-2923-2844], Magazzù, Alessandro [0000-0003-1247-2702], Bronte Ciriza, David [0000-0002-5874-6601], Iatì, Maria Antonia [0000-0002-3576-8656], Swartzlander, Grover A. [0000-0003-3513-2225], Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A. R., Moreira, Wendel L., Fontes, Adriana, César, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F. D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, Pérez García, Laura, Arzola, Alejandro V., Pérez Castillo, Isaac, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Tello Marmolejo, Javier, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Félix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Bronte Ciriza, David, Iatì, Maria Antonia, Swartzlander, Grover A., NASA Innovative Advanced Concepts, Australian Research Council, Japan Society for the Promotion of Science, Boğaziçi Üniversity, Novo Nordisk UK Research Foundation, Knut and Alice Wallenberg Foundation, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Universidad Autónoma de Madrid, Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brasil), Universidade Federal do Ceará, Agenzia Spaziale Italiana, Istituto Nazionale di Astrofisica, Agence Nationale de la Recherche (France), Wellcome Trust, Austrian Science Fund, Universidad Nacional Autónoma de México, European Commission, European Research Council, German Research Foundation, Natural Sciences and Engineering Research Council of Canada, Swedish Research Council, Engineering and Physical Sciences Research Council (UK), Office of Naval Research (US), National Science Foundation (US), Institute of Geology of the Czech Academy of Sciences, Czech Science Foundation, Generalitat de Catalunya, University of Münster, Department of Science and Technology (India), Human Frontier Science Program, Biotechnology and Biological Sciences Research Council (UK), Medical Research Council (UK), Danish National Research Foundation, Independent Research Fund Denmark, Beckman Institute, Associazione Italiana per la Ricerca sul Cancro, Volpe, Giovanni [0000-0001-5057-1846], Maragò, Onofrio M. [0000-0002-7220-8527], Rubinsztein-Dunlop, Halina [0000-0002-8332-2309], Stilgoe, Alexander B. [0000-0002-9299-5695], Volpe, Giorgio [0000-0001-9993-5348], Truong, Viet Giang [0000-0003-3589-7850], Chormaic, Síle Nic [0000-0003-4276-2014], Elahi, Parviz [0000-0003-3545-8436], Käll, Mikael [0000-0002-1163-0345], Callegari, Agnese [0000-0002-4488-4106], Neves, Antonio A. R. [0000-0002-2615-8573], Eismann, Jörg S. [0000-0002-2495-4613], Banzer, Peter [0000-0002-6336-6953], Roy, Basudev [0000-0003-0737-2889], Thalhammer-Thurner, Gregor [0000-0002-3948-8045], Ritsch-Marte, Monika [0000-0002-5945-546X], Pérez Castillo, Isaac0000-0001-7622-9440, Muenker, Till M. [0000-0003-3225-8746], Vos, Bart E. [0000-0002-4325-6298], Betz, Timo [0000-0002-1548-0655], Reece, Peter J. [0000-0003-4852-3735], McGloin, David [0000-0002-0075-4481], Gordon, Reuven [0000-0002-1485-6067], Bruce, Graham D. [0000-0003-3403-0614], Dholakia, Kishan [0000-0001-6534-9009], Roichman, Yael [0000-0003-1927-4506], Bobkova, Valeriia [0000-0003-4080-9069], Wittkowski, Raphael [0000-0003-4881-9173], Denz, Cornelia [0000-0002-7292-2499], Pavan Kumar, G. V. [0000-0002-4036-7187], Foti, Antonino [0000-0002-9824-3099], Donato, Maria Grazia [0000-0002-7580-3137], Gucciardi, Pietro G. [0000-0003-1826-9174], Gardini, Lucia [0000-0003-0923-9221], Kashchuk, Anatolii V. [0000-0002-2364-9393], Capitanio, Marco [0000-0002-9799-9353], Paterson, Lynn [0000-0003-0493-5041], Jones, Philip H. [0000-0002-0860-631X], Berg-Sørensen, Kirstine [0000-0002-9977-3980], Oddershede, Lene B. [0000-0003-2923-2844], Magazzù, Alessandro [0000-0003-1247-2702], Bronte Ciriza, David [0000-0002-5874-6601], Iatì, Maria Antonia [0000-0002-3576-8656], Swartzlander, Grover A. [0000-0003-3513-2225], Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A. R., Moreira, Wendel L., Fontes, Adriana, César, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F. D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, Pérez García, Laura, Arzola, Alejandro V., Pérez Castillo, Isaac, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Tello Marmolejo, Javier, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Félix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Bronte Ciriza, David, Iatì, Maria Antonia, and Swartzlander, Grover A.

Abstract

Optical tweezers are tools made of light that enable contactless pushing, trapping, and manipulation of objects, ranging from atoms to space light sails. Since the pioneering work by Arthur Ashkin in the 1970s, optical tweezers have evolved into sophisticated instruments and have been employed in a broad range of applications in the life sciences, physics, and engineering. These include accurate force and torque measurement at the femtonewton level, microrheology of complex fluids, single micro- and nano-particle spectroscopy, single-cell analysis, and statistical-physics experiments. This roadmap provides insights into current investigations involving optical forces and optical tweezers from their theoretical foundations to designs and setups. It also offers perspectives for applications to a wide range of research fields, from biophysics to space exploration.

Published
2023

6. Roadmap for optical tweezers

Author

Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A.R., Moreira, Wendel L., Fontes, Adriana, Cesar, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F.D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, García, Laura Pérez, Arzola, Alejandro V., Castillo, Isaac Pérez, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Marmolejo, Javier Tello, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Felix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Ciriza, David Bronte, Iatì, Maria Antonia, Swartzlander, Grover A., Volpe, Giovanni, Maragò, Onofrio M., Rubinsztein-Dunlop, Halina, Pesce, Giuseppe, Stilgoe, Alexander B., Volpe, Giorgio, Tkachenko, Georgiy, Truong, Viet Giang, Chormaic, Síle Nic, Kalantarifard, Fatemeh, Elahi, Parviz, Käll, Mikael, Callegari, Agnese, Marqués, Manuel I., Neves, Antonio A.R., Moreira, Wendel L., Fontes, Adriana, Cesar, Carlos L., Saija, Rosalba, Saidi, Abir, Beck, Paul, Eismann, Jörg S., Banzer, Peter, Fernandes, Thales F.D., Pedaci, Francesco, Bowen, Warwick P., Vaippully, Rahul, Lokesh, Muruga, Roy, Basudev, Thalhammer-Thurner, Gregor, Ritsch-Marte, Monika, García, Laura Pérez, Arzola, Alejandro V., Castillo, Isaac Pérez, Argun, Aykut, Muenker, Till M., Vos, Bart E., Betz, Timo, Cristiani, Ilaria, Minzioni, Paolo, Reece, Peter J., Wang, Fan, McGloin, David, Ndukaife, Justus C., Quidant, Romain, Roberts, Reece P., Laplane, Cyril, Volz, Thomas, Gordon, Reuven, Hanstorp, Dag, Marmolejo, Javier Tello, Bruce, Graham D., Dholakia, Kishan, Li, Tongcang, Brzobohatý, Oto, Simpson, Stephen H., Zemánek, Pavel, Ritort, Felix, Roichman, Yael, Bobkova, Valeriia, Wittkowski, Raphael, Denz, Cornelia, Pavan Kumar, G. V., Foti, Antonino, Donato, Maria Grazia, Gucciardi, Pietro G., Gardini, Lucia, Bianchi, Giulio, Kashchuk, Anatolii V., Capitanio, Marco, Paterson, Lynn, Jones, Philip H., Berg-Sørensen, Kirstine, Barooji, Younes F., Oddershede, Lene B., Pouladian, Pegah, Preece, Daryl, Adiels, Caroline Beck, De Luca, Anna Chiara, Magazzù, Alessandro, Ciriza, David Bronte, Iatì, Maria Antonia, and Swartzlander, Grover A.

Abstract

Optical tweezers are tools made of light that enable contactless pushing, trapping, and manipulation of objects, ranging from atoms to space light sails. Since the pioneering work by Arthur Ashkin in the 1970s, optical tweezers have evolved into sophisticated instruments and have been employed in a broad range of applications in the life sciences, physics, and engineering. These include accurate force and torque measurement at the femtonewton level, microrheology of complex fluids, single micro- and nano-particle spectroscopy, single-cell analysis, and statistical-physics experiments. This roadmap provides insights into current investigations involving optical forces and optical tweezers from their theoretical foundations to designs and setups. It also offers perspectives for applications to a wide range of research fields, from biophysics to space exploration.

Published
2023

7. HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party

Author

Mikulska, M., Penack, O., Wendel, L., Knelange, N., Cornelissen, J.J.L.M, Blijlevens, N.M., Passweg, J., Kroger, N., Bruns, A., Koenecke, C., Bierings, M., Piñana, J.L., Labussiere-Wallet, H., Ghesquieres, H., Diaz, M.A., Sampol, A., Averbuch, D., Camara, R. de la, Styczynski, J., Mikulska, M., Penack, O., Wendel, L., Knelange, N., Cornelissen, J.J.L.M, Blijlevens, N.M., Passweg, J., Kroger, N., Bruns, A., Koenecke, C., Bierings, M., Piñana, J.L., Labussiere-Wallet, H., Ghesquieres, H., Diaz, M.A., Sampol, A., Averbuch, D., Camara, R. de la, and Styczynski, J.

Abstract

Item does not contain fulltext, HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in 6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.

Published
2022

8. HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party

Author

Mikulska, M., Penack, O., Wendel, L., Knelange, N., Cornelissen, J.J.L.M, Blijlevens, N.M., Passweg, J., Kroger, N., Bruns, A., Koenecke, C., Bierings, M., Piñana, J.L., Labussiere-Wallet, H., Ghesquieres, H., Diaz, M.A., Sampol, A., Averbuch, D., Camara, R. de la, Styczynski, J., Mikulska, M., Penack, O., Wendel, L., Knelange, N., Cornelissen, J.J.L.M, Blijlevens, N.M., Passweg, J., Kroger, N., Bruns, A., Koenecke, C., Bierings, M., Piñana, J.L., Labussiere-Wallet, H., Ghesquieres, H., Diaz, M.A., Sampol, A., Averbuch, D., Camara, R. de la, and Styczynski, J.

Abstract

Item does not contain fulltext, HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in 6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.

Published
2022

9. Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Averbuch, D., Greef, J. van der, Duréault, A., Wendel, L., Tridello, G., Lebeaux, D., Mikulska, M., Gil, L., Knelange, N., Zuckerman, T., Roussel, X., Robin, C., Xhaard, A., Aljurf, M., Beguin, Y., Bourgeois, A. Le, Botella-Garcia, C., Khanna, N., Praet, J. Van, Kröger, N., Blijlevens, N.M.A., Ducastelle Leprêtre, S., Ho, A., Roos-Weil, D., Yeshurun, M., Lortholary, O., Fontanet, A., Camara, R. de la, Coussement, J., Maertens, J., Styczynski, J., Averbuch, D., Greef, J. van der, Duréault, A., Wendel, L., Tridello, G., Lebeaux, D., Mikulska, M., Gil, L., Knelange, N., Zuckerman, T., Roussel, X., Robin, C., Xhaard, A., Aljurf, M., Beguin, Y., Bourgeois, A. Le, Botella-Garcia, C., Khanna, N., Praet, J. Van, Kröger, N., Blijlevens, N.M.A., Ducastelle Leprêtre, S., Ho, A., Roos-Weil, D., Yeshurun, M., Lortholary, O., Fontanet, A., Camara, R. de la, Coussement, J., Maertens, J., and Styczynski, J.

Abstract

Item does not contain fulltext, BACKGROUND: Nocardiosis is rare after hematopoietic cell transplantation (HCT). Little is known regarding its presentation, management, and outcome in this population. METHODS: This retrospective international study reviewed nocardiosis episodes in HCT recipients (1/1/2000-31/12/2018; 135 transplant centers; 33 countries) and described their clinical, microbiological, radiological, and outcome characteristics. RESULTS: We identified 81 nocardiosis episodes in 74 allo- and 7 auto-HCT recipients. Nocardiosis occurred a median of 8 (IQR: 4-18) months post-HCT. The most frequently involved organs were lungs (70/81; 86%) and brain (30/81; 37%); 29 (36%) patients were afebrile; 46/81 (57%) had disseminated infections. The most common lung imaging findings were consolidations (33/68; 49%) or nodules (32/68; 47%); brain imaging findings were multiple brain abscesses (19/30; 63%). Ten of 30 (33%) patients with brain involvement lacked neurological symptoms. Fourteen of 48 (29%) patients were bacteremic. Nocardia farcinica was the most common among molecularly identified species (27%; 12/44). Highest susceptibility rates were reported to linezolid (45/45; 100%), amikacin (56/57; 98%), trimethoprim-sulfamethoxazole (57/63; 90%), and imipenem (49/57; 86%). One-year and last follow-up (IQR: 4-42.5 months) all-cause mortality were 40% (32/81) and 52% (42/81), respectively. In the multivariable analysis, underlying disease not in complete remission (HR: 2.81; 95% CI: 1.32-5.95) and prior bacterial infection (HR: 3.42; 95% CI: 1.62-7.22) were associated with higher 1-year all-cause mortality. CONCLUSIONS: Nocardiosis is a late post-HCT infection usually manifesting as a pulmonary disease with frequent dissemination, brain infection, and bacteremia. Brain imaging should be performed in HCT recipients with nocardiosis regardless of neurological symptoms. Overall mortality is high.

Published
2022

10. HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party

Author

Mikulska, M., Penack, O., Wendel, L., Knelange, N., Cornelissen, J.J.L.M, Blijlevens, N.M., Passweg, J., Kroger, N., Bruns, A., Koenecke, C., Bierings, M., Piñana, J.L., Labussiere-Wallet, H., Ghesquieres, H., Diaz, M.A., Sampol, A., Averbuch, D., Camara, R. de la, Styczynski, J., Mikulska, M., Penack, O., Wendel, L., Knelange, N., Cornelissen, J.J.L.M, Blijlevens, N.M., Passweg, J., Kroger, N., Bruns, A., Koenecke, C., Bierings, M., Piñana, J.L., Labussiere-Wallet, H., Ghesquieres, H., Diaz, M.A., Sampol, A., Averbuch, D., Camara, R. de la, and Styczynski, J.

Abstract

Item does not contain fulltext, HEV infection is an emerging cause of acute and chronic hepatitis in stem cell transplant (SCT) recipients. We performed a retrospective observational study among EBMT centers with the aim of describing characteristics, management and outcome of HEV after SCT. There were 34 cases of HEV infection from 12 centers in 6 countries, diagnosed in median 4.5 months after SCT; 20 of acute and 14 of chronic infection. Non-hepatic findings possibly associated with HEV infection were present in 9 (26%). Patients with chronic infection had more characteristics associated with severely immunocompromised status. Ribavirin was provided to 16 patients (47%; 40% with acute and 57% with chronic infection), in median for 75 days. Three (19%) patients discontinued it due to side effects. HEV-RNA clearance occurred in 29 patients (85%; 85% in acute and 86% in chronic infection). HEV was considered a cause of death in 3 (9%), with 2 cases with late diagnosis. Reduction of immunosuppression in those receiving it, and ribavirin treatment in those with chronic infection were associated with shorter time to HEV-RNA clearance. Policy on HEV testing varied between the centers. In conclusion, acute and chronic HEV hepatitis should be promptly diagnosed and managed in SCT recipients.

Published
2022

11. Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

Author

Averbuch, D., Greef, J. van der, Duréault, A., Wendel, L., Tridello, G., Lebeaux, D., Mikulska, M., Gil, L., Knelange, N., Zuckerman, T., Roussel, X., Robin, C., Xhaard, A., Aljurf, M., Beguin, Y., Bourgeois, A. Le, Botella-Garcia, C., Khanna, N., Praet, J. Van, Kröger, N., Blijlevens, N.M.A., Ducastelle Leprêtre, S., Ho, A., Roos-Weil, D., Yeshurun, M., Lortholary, O., Fontanet, A., Camara, R. de la, Coussement, J., Maertens, J., Styczynski, J., Averbuch, D., Greef, J. van der, Duréault, A., Wendel, L., Tridello, G., Lebeaux, D., Mikulska, M., Gil, L., Knelange, N., Zuckerman, T., Roussel, X., Robin, C., Xhaard, A., Aljurf, M., Beguin, Y., Bourgeois, A. Le, Botella-Garcia, C., Khanna, N., Praet, J. Van, Kröger, N., Blijlevens, N.M.A., Ducastelle Leprêtre, S., Ho, A., Roos-Weil, D., Yeshurun, M., Lortholary, O., Fontanet, A., Camara, R. de la, Coussement, J., Maertens, J., and Styczynski, J.

Abstract

Contains fulltext : 282627.pdf (Publisher’s version ) (Closed access), BACKGROUND: Nocardiosis is rare after hematopoietic cell transplantation (HCT). Little is known regarding its presentation, management, and outcome in this population. METHODS: This retrospective international study reviewed nocardiosis episodes in HCT recipients (1/1/2000-31/12/2018; 135 transplant centers; 33 countries) and described their clinical, microbiological, radiological, and outcome characteristics. RESULTS: We identified 81 nocardiosis episodes in 74 allo- and 7 auto-HCT recipients. Nocardiosis occurred a median of 8 (IQR: 4-18) months post-HCT. The most frequently involved organs were lungs (70/81; 86%) and brain (30/81; 37%); 29 (36%) patients were afebrile; 46/81 (57%) had disseminated infections. The most common lung imaging findings were consolidations (33/68; 49%) or nodules (32/68; 47%); brain imaging findings were multiple brain abscesses (19/30; 63%). Ten of 30 (33%) patients with brain involvement lacked neurological symptoms. Fourteen of 48 (29%) patients were bacteremic. Nocardia farcinica was the most common among molecularly identified species (27%; 12/44). Highest susceptibility rates were reported to linezolid (45/45; 100%), amikacin (56/57; 98%), trimethoprim-sulfamethoxazole (57/63; 90%), and imipenem (49/57; 86%). One-year and last follow-up (IQR: 4-42.5 months) all-cause mortality were 40% (32/81) and 52% (42/81), respectively. In the multivariable analysis, underlying disease not in complete remission (HR: 2.81; 95% CI: 1.32-5.95) and prior bacterial infection (HR: 3.42; 95% CI: 1.62-7.22) were associated with higher 1-year all-cause mortality. CONCLUSIONS: Nocardiosis is a late post-HCT infection usually manifesting as a pulmonary disease with frequent dissemination, brain infection, and bacteremia. Brain imaging should be performed in HCT recipients with nocardiosis regardless of neurological symptoms. Overall mortality is high.

Published
2022

12. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study

Author

Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., Ljungman, P., Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., and Ljungman, P.

Abstract

Item does not contain fulltext, Letermovir (LMV) is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV-seropositive patients. Due to its favorable safety profile, LMV brings potential for use in other clinical situations, outside the approved indication. The objective of the study was to analyze the efficacy and safety of the use of LMV in off-label indications in EBMT centers. A total of 49 patients were reported including 44 adults and 5 children. LMV was administered for: secondary prophylaxis (37 adults, 3 children), primary prophylaxis (2 children), pre-emptive treatment (5 adults), and therapy of CMV disease (2 adults; pneumonia, colitis). Cyclosporine was concomitantly used in 26 patients. Overall, LMV was used for a median 112 days (range: 10-473). Cumulative incidence of breakthrough infections during secondary prophylaxis was 10.1% (95% CI = 3.1-21.9). Prophylactic treatment with LMV resulted in 94.9% (95% CI = 81.0-98.7), and 81.9% (95% CI = 65.7-90.9) probability of, respectively, 60 and 120-day survival without CMV infection in patients receiving secondary prophylaxis. During therapy of CMV infection/disease, probability of 60 and 120-day overall survival was 100% and 71.4% (95% CI = 25.8-92.0), respectively. No breakthrough infection occurred in children on LMV prophylaxis. Adverse events were reported in 15/49 (30.4%) patients: the most common being nausea/vomiting (22.4%). In conclusion, the efficacy of the use of LMV as secondary prophylaxis was high, and the preliminary experience with the use of LMV for the treatment of patients with refractory CMV infection/disease was positive. Our data showed that higher dose or prolonged therapy did not result in increased rate of adverse events.

Published
2021

13. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study

Author

Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., Ljungman, P., Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., and Ljungman, P.

Abstract

Item does not contain fulltext, Letermovir (LMV) is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV-seropositive patients. Due to its favorable safety profile, LMV brings potential for use in other clinical situations, outside the approved indication. The objective of the study was to analyze the efficacy and safety of the use of LMV in off-label indications in EBMT centers. A total of 49 patients were reported including 44 adults and 5 children. LMV was administered for: secondary prophylaxis (37 adults, 3 children), primary prophylaxis (2 children), pre-emptive treatment (5 adults), and therapy of CMV disease (2 adults; pneumonia, colitis). Cyclosporine was concomitantly used in 26 patients. Overall, LMV was used for a median 112 days (range: 10-473). Cumulative incidence of breakthrough infections during secondary prophylaxis was 10.1% (95% CI = 3.1-21.9). Prophylactic treatment with LMV resulted in 94.9% (95% CI = 81.0-98.7), and 81.9% (95% CI = 65.7-90.9) probability of, respectively, 60 and 120-day survival without CMV infection in patients receiving secondary prophylaxis. During therapy of CMV infection/disease, probability of 60 and 120-day overall survival was 100% and 71.4% (95% CI = 25.8-92.0), respectively. No breakthrough infection occurred in children on LMV prophylaxis. Adverse events were reported in 15/49 (30.4%) patients: the most common being nausea/vomiting (22.4%). In conclusion, the efficacy of the use of LMV as secondary prophylaxis was high, and the preliminary experience with the use of LMV for the treatment of patients with refractory CMV infection/disease was positive. Our data showed that higher dose or prolonged therapy did not result in increased rate of adverse events.

Published
2021

14. Nocardia infections in hematopoietic cell transplant recipients: a multicenter international retrospective study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Averbuch, D, De Greef, Julien, Duréault, A, Wendel, L, Tridello, G, Lebeaux, D, Mikulska, M, Gil, L, Knelange, N, Zuckerman, T, Roussel, X, Robin, C, Xhaard, A, Aljurf, M, Beguin, Y, Le Bourgeois, A, Botella-Garcia, C, Khanna, N, Van Praet, J, Kröger, N, Blijlevens, N, Ducastelle Leprêtre, S, Ho, A, Roos-Weil, D, Yeshurun, M, Lortholary, O, Fontanet, A, de la Camara, R, Coussement, J, Maertens, J, Styczynski, J, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Averbuch, D, De Greef, Julien, Duréault, A, Wendel, L, Tridello, G, Lebeaux, D, Mikulska, M, Gil, L, Knelange, N, Zuckerman, T, Roussel, X, Robin, C, Xhaard, A, Aljurf, M, Beguin, Y, Le Bourgeois, A, Botella-Garcia, C, Khanna, N, Van Praet, J, Kröger, N, Blijlevens, N, Ducastelle Leprêtre, S, Ho, A, Roos-Weil, D, Yeshurun, M, Lortholary, O, Fontanet, A, de la Camara, R, Coussement, J, Maertens, J, and Styczynski, J

Abstract

BACKGROUND: Nocardiosis is rare after hematopoietic cell transplantation (HCT). Little is known regarding its presentation, management, and outcome in this population. METHODS: In this retrospective international study, we reviewed nocardiosis episodes in HCT recipients (01.01.2000-31.12.2018; 135 transplant centers; 33 countries) and described their clinical, microbiological, radiological, and outcome characteristics. RESULTS: We identified 81 nocardiosis episodes in 74 allo- and 7 auto-HCT recipients. Nocardiosis occurred at a median of 8 (IQR 4-18) months post-HCT. The most frequently involved organs were lungs (70/81; 86%) and brain (30/81; 37%); 29 (36%) patients were afebrile; 46/81 (57%) had disseminated infections. The most common lung imaging findings were consolidations (33/68; 49%) or nodules (32/68; 47%); and brain imaging findings were multiple brain abscesses (19/30; 63%). 10/30 (33%) patients with brain involvement lacked neurological symptoms. 14/48 (29%) patients were bacteremic. N. farcinica was the most common among molecularly identified species (27%, 12/44). Highest susceptibility rates were reported to linezolid 45/45 (100%), amikacin 56/57 (98%), trimethoprim-sulfamethoxazole 57/63 (90%), and imipenem 49/57 (86%).One-year and last follow-up (IQR: 4-42.5 months) all-cause mortality were 40% (32/81) and 52% (42/81), respectively. In the multivariable analysis, underlying disease not in complete remission (HR 2.81, 95%CI 1.32-5.95), and prior bacterial infection (HR 3.42, 95%CI 1.62-7.22) were associated with higher one-year all-cause mortality. CONCLUSIONS: Nocardiosis is a late post-HCT infection usually manifesting as a pulmonary disease with frequent dissemination, brain infection and bacteremia. Brain imaging should be performed in HCT recipients with nocardiosis regardless of neurological symptoms. Overall mortality is high.

Published
2021

15. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study

Author

Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., Ljungman, P., Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., and Ljungman, P.

Abstract

Item does not contain fulltext, Letermovir (LMV) is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV-seropositive patients. Due to its favorable safety profile, LMV brings potential for use in other clinical situations, outside the approved indication. The objective of the study was to analyze the efficacy and safety of the use of LMV in off-label indications in EBMT centers. A total of 49 patients were reported including 44 adults and 5 children. LMV was administered for: secondary prophylaxis (37 adults, 3 children), primary prophylaxis (2 children), pre-emptive treatment (5 adults), and therapy of CMV disease (2 adults; pneumonia, colitis). Cyclosporine was concomitantly used in 26 patients. Overall, LMV was used for a median 112 days (range: 10-473). Cumulative incidence of breakthrough infections during secondary prophylaxis was 10.1% (95% CI = 3.1-21.9). Prophylactic treatment with LMV resulted in 94.9% (95% CI = 81.0-98.7), and 81.9% (95% CI = 65.7-90.9) probability of, respectively, 60 and 120-day survival without CMV infection in patients receiving secondary prophylaxis. During therapy of CMV infection/disease, probability of 60 and 120-day overall survival was 100% and 71.4% (95% CI = 25.8-92.0), respectively. No breakthrough infection occurred in children on LMV prophylaxis. Adverse events were reported in 15/49 (30.4%) patients: the most common being nausea/vomiting (22.4%). In conclusion, the efficacy of the use of LMV as secondary prophylaxis was high, and the preliminary experience with the use of LMV for the treatment of patients with refractory CMV infection/disease was positive. Our data showed that higher dose or prolonged therapy did not result in increased rate of adverse events.

Published
2021

16. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study

Author

Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., Ljungman, P., Styczyński, J., Tridello, G., Xhaard, A., Medinger, M., Mielke, S., Taskinen, M., Blijlevens, N.M.A., Rodriguez, Mabel, Solano, C., Nikolousis, E., Biffi, A., Groll, A.H., Junghanss, C., Tsirigotis, P., Lioure, B., Šrámek, J., Holler, E., Galaverna, F., Fagioli, F., Knelange, N., Wendel, L., Gil, L., Camara, R. de la, Mikulska, M., and Ljungman, P.

Abstract

Item does not contain fulltext, Letermovir (LMV) is licensed for prophylaxis of CMV infection in allogeneic hematopoietic cell transplant adult CMV-seropositive patients. Due to its favorable safety profile, LMV brings potential for use in other clinical situations, outside the approved indication. The objective of the study was to analyze the efficacy and safety of the use of LMV in off-label indications in EBMT centers. A total of 49 patients were reported including 44 adults and 5 children. LMV was administered for: secondary prophylaxis (37 adults, 3 children), primary prophylaxis (2 children), pre-emptive treatment (5 adults), and therapy of CMV disease (2 adults; pneumonia, colitis). Cyclosporine was concomitantly used in 26 patients. Overall, LMV was used for a median 112 days (range: 10-473). Cumulative incidence of breakthrough infections during secondary prophylaxis was 10.1% (95% CI = 3.1-21.9). Prophylactic treatment with LMV resulted in 94.9% (95% CI = 81.0-98.7), and 81.9% (95% CI = 65.7-90.9) probability of, respectively, 60 and 120-day survival without CMV infection in patients receiving secondary prophylaxis. During therapy of CMV infection/disease, probability of 60 and 120-day overall survival was 100% and 71.4% (95% CI = 25.8-92.0), respectively. No breakthrough infection occurred in children on LMV prophylaxis. Adverse events were reported in 15/49 (30.4%) patients: the most common being nausea/vomiting (22.4%). In conclusion, the efficacy of the use of LMV as secondary prophylaxis was high, and the preliminary experience with the use of LMV for the treatment of patients with refractory CMV infection/disease was positive. Our data showed that higher dose or prolonged therapy did not result in increased rate of adverse events.

Published
2021

17. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

Author

Battipaglia, G., Mauff, K., Wendel, L., Angelucci, E., Mohty, M., Arcese, W., Santarone, S., Rubio, M. T., Kroger, N., Fox, M. L., Blaise, D., Iori, A. P., Fanin, R., Chalandon, Y., Pioltelli, P., Marotta, G., Chiusolo, Patrizia, Sever, M., Solano, C., Contentin, N., de Wreede, L. C., Czerw, T., Hernandez-Boluda, J. C., Hayden, P., Mclornan, D., Yakoub-Agha, I., Chiusolo P. (ORCID:0000-0002-1355-1587), Battipaglia, G., Mauff, K., Wendel, L., Angelucci, E., Mohty, M., Arcese, W., Santarone, S., Rubio, M. T., Kroger, N., Fox, M. L., Blaise, D., Iori, A. P., Fanin, R., Chalandon, Y., Pioltelli, P., Marotta, G., Chiusolo, Patrizia, Sever, M., Solano, C., Contentin, N., de Wreede, L. C., Czerw, T., Hernandez-Boluda, J. C., Hayden, P., Mclornan, D., Yakoub-Agha, I., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option in MF. There is no consensus on the optimal conditioning regimen. We report outcomes of 187 patients with MF transplanted between 2010 and 2017 conditioned with TBF. Median age was 58 years. Median interval from diagnosis to allo-HCT was 44 months. Donors were haploidentical (41%), unrelated (36%) or HLA-identical siblings (23%). Stem cell source was PB in 60%. Conditioning was myeloablative in 48% of cases. Antithymocyte globulin (ATG) was used in 41% of patients. At 100 days, neutrophil and platelet engraftment were 91% and 63% after a median of 21 and 34 days, respectively. Grade II-IV and III-IV acute GVHD occurred in 24% and 12%, while at 3 years, all grade chronic GVHD and chronic extensive GVHD had been diagnosed in 38% and 11%. At 3 years, OS, RFS and GRFS were 55%, 49% and 43%, respectively. RI and NRM were 17% and 33%. On multivariate analysis, poor KPS and the use of unrelated donors were associated with worse GRFS and a higher grade II-IV acute GVHD, respectively. Neither donor type nor intensity of the conditioning regimen influenced survival outcomes. TBF is a feasible conditioning regimen in allo-HCT for MF in all donor settings although longer term outcomes are required.

Published
2021

18. Early probiotic supplementation and the risk of celiac disease in children at genetic risk

Author

Uusitalo, U. (Ulla), Aronsson, C. A. (Carin Andren), Liu, X. (Xiang), Kurppa, K. (Kalle), Yang, J. (Jimin), Liu, E. (Edwin), Skidmore, J. (Jennifer), Winkler, C. (Christiane), Rewers, M. J. (Marian J.), Hagopian, W. A. (William A.), She, J.-X. (Jin-Xiong), Toppari, J. (Jorma), Ziegler, A.-G. (Anette-G), Akolkar, B. (Beena), Norris, J. M. (Jill M.), Virtanen, S. M. (Suvi M.), Krischer, J. P. (Jeffrey P.), Agardh, D. (Daniel), Rewers, M. (Marian), Bautista, K. (Kimberly), Baxter, J. (Judith), Felipe-Morales, D. (Daniel), Driscoll, K. (Kimberly), Frohnert, B. I. (Brigitte, I), Gallant, M. (Marisa), Gesualdo, P. (Patricia), Hoffman, M. (Michelle), Karban, R. (Rachel), Norris, J. (Jill), Steck, A. (Andrea), Waugh, K. (Kathleen), Simell, O. G. (Olli G.), Adamsson, A. (Annika), Ahonen, S. (Suvi), Akerlund, M. (Mari), Hekkala, A. (Anne), Holappa, H. (Henna), Hyoty, H. (Heikki), Ikonen, A. (Anni), Ilonen, J. (Jorma), Jaminki, S. (Sinikka), Jokipuu, S. (Sanna), Karlsson, L. (Leena), Kahonen, M. (Miia), Knip, M. (Mikael), Koivikko, M.-L. (Minna-Liisa), Koreasalo, M. (Mirva), Kytola, J. (Jarita), Latva-aho, T. (Tiina), Lindfors, K. (Katri), Lonnrot, M. (Maria), Mantymaki, E. (Elina), Mattila, M. (Markus), Multasuo, K. (Katja), Mykkanenv, T. (Teija), Niininen, T. (Titha), Niinisto, S. (Sari), Nyblom, M. (Mia), Oikarinen, S. (Sami), Ollikainen, P. (Paula), Pohjola, S. (Sirpa), Rajala, P. (Petra), Rautanen, J. (Jenna), Riikonen, A. (Anne), Romo, M. (Minna), Ruohonen, S. (Suvi), Simell, S. (Satu), Sjoberg, M. (Maija), Stenius, A. (Aino), Tossavainen, P. (Paivi), Vaha-Makila, M. (Mari), Vainionpaa, S. (Sini), Varjonen, E. (Eeva), Veijola, R. (Riitta), Viinikangas, I. (Irene), Schatz, D. (Desmond), Hopkins, D. (Diane), Steed, L. (Leigh), Bryant, J. (Jennifer), Silvis, K. (Katherine), Haller, M. (Michael), Gardiner, M. (Melissa), Mclndoe, R. (Richard), Sharma, A. (Ashok), Anderson, S. W. (Stephen W.), Jacobsen, L. (Laura), Marks, J. (John), Towe, P. D. (P. D.), Ziegler, A. G. (Anette G.), Bonifacio, E. (Ezio), D'Angelo, M. (Miryam), Gavrisan, A. (Anita), Gezginci, C. (Cigdem), Heublein, A. (Anja), Hoffmann, V. (Verena), Hummel, S. (Sandra), Keimer, A. (Andrea), Knopff, A. (Annette), Koch, C. (Charlotte), Koletzko, S. (Sibylle), Ramminger, C. (Claudia), Roth, R. (Roswith), Scholz, M. (Marlon), Stock, J. (Joanna), Warncke, K. (Katharina), Wendel, L. (Lorena), Lernmark, A. (Ake), Ask, M. (Maria), Bremer, J. (Jenny), Cilio, C. (Corrado), Ericson-Hallstrom, E. (Emelie), Fors, A. (Annika), Fransson, L. (Lina), Gard, T. (Thomas), Bennet, R. (Rasmus), Hansen, M. (Monika), Hyberg, S. (Susanne), Jisser, H. (Hanna), Johansen, F. (Fredrik), Jonsdottir, B. (Berglind), Jovic, S. (Silvija), Larsson, H. E. (Helena Elding), Lindstrom, M. (Marielle), Lundgren, M. (Markus), Manson-Martinez, M. (Maria), Markan, M. (Maria), Melin, J. (Jessica), Mestan, Z. (Zeliha), Nilsson, C. (Caroline), Ottosson, K. (Karin), Rahmati, K. (Kobra), Ramelius, A. (Anita), Salami, F. (Falastin), Sjoberg, A. (Anette), Sjoberg, B. (Birgitta), Torn, C. (Carina), Wallin, A. (Anne), Wimar, A. (Asa), Aberg, S. (Sofie), Killian, M. (Michael), Crouch, C. C. (Claire Cowen), Akramoff, A. (Ashley), Chavoshi, M. (Masumeh), Dunson, K. (Kayleen), Hervey, R. (Rachel), Lyons, R. (Rachel), Meyer, A. (Arlene), Mulenga, D. (Denise), Radtke, J. (Jared), Romancik, M. (Matei), Schmitt, D. (Davey), Schwabe, J. (Julie), Zink, S. (Sarah), Becker, D. (Dorothy), Franciscus, M. (Margaret), Smith, M. D. (Maryellen Dalmagro-Elias), Daftary, A. (Ashi), Klein, M. B. (Mary Beth), Yates, C. (Chrystal), Austin-Gonzalez, S. (Sarah), Avendano, M. (Maryouri), Baethke, S. (Sandra), Brown, R. (Rasheedah), Burkhardt, B. (Brant), Butterworth, M. (Martha), Clasen, J. (Joanna), Cuthbertson, D. (David), Eberhard, C. (Christopher), Fiske, S. (Steven), Garmeson, J. (Jennifer), Gowda, V. (Veena), Heyman, K. (Kathleen), Hsiao, B. (Belinda), Karges, C. (Christina), Laras, F. P. (Francisco Perez), Lee, H.-S. (Hye-Seung), Li, Q. (Qian), Liu, S. (Shu), Lynch, K. (Kristian), Maguire, C. (Colleen), Malloy, J. (Jamie), McCarthy, C. (Cristina), Merrell, A. (Aubrie), Meulemans, S. (Steven), Parikh, H. (Hemang), Quigley, R. (Ryan), Remedios, C. (Cassandra), Shaffer, C. (Chris), Smith, L. (Laura), Smith, S. (Susan), Sulman, N. (Noah), Tamura, R. (Roy), Tewey, D. (Dena), Toth, M. (Michael), Vehik, K. (Kendra), Vijayakandipan, P. (Ponni), Wood, K. (Keith), Abbondondolo, M. (Michael), Ballard, L. (Lori), Hadley, D. (David), McLeod, W. (Wendy), Yu, L. (Liping), Miao, D. (Dongmei), Bingley, P. (Polly), Williams, A. (Alistair), Chandler, K. (Kyla), Ball, O. (Olivia), Kelland, I. (Ilana), Grace, S. (Sian), . (), Hagopian, W. (William), Erlich, H. (Henry), Mack, S. J. (Steven J.), Fear, A. L. (Anna Lisa), Ke, S. (Sandra), Mulholland, N. (Niveen), Bourcier, K. (Kasia), Briese, T. (Thomas), Johnson, S. B. (Suzanne Bennett), Triplett, E. (Eric), Uusitalo, U. (Ulla), Aronsson, C. A. (Carin Andren), Liu, X. (Xiang), Kurppa, K. (Kalle), Yang, J. (Jimin), Liu, E. (Edwin), Skidmore, J. (Jennifer), Winkler, C. (Christiane), Rewers, M. J. (Marian J.), Hagopian, W. A. (William A.), She, J.-X. (Jin-Xiong), Toppari, J. (Jorma), Ziegler, A.-G. (Anette-G), Akolkar, B. (Beena), Norris, J. M. (Jill M.), Virtanen, S. M. (Suvi M.), Krischer, J. P. (Jeffrey P.), Agardh, D. (Daniel), Rewers, M. (Marian), Bautista, K. (Kimberly), Baxter, J. (Judith), Felipe-Morales, D. (Daniel), Driscoll, K. (Kimberly), Frohnert, B. I. (Brigitte, I), Gallant, M. (Marisa), Gesualdo, P. (Patricia), Hoffman, M. (Michelle), Karban, R. (Rachel), Norris, J. (Jill), Steck, A. (Andrea), Waugh, K. (Kathleen), Simell, O. G. (Olli G.), Adamsson, A. (Annika), Ahonen, S. (Suvi), Akerlund, M. (Mari), Hekkala, A. (Anne), Holappa, H. (Henna), Hyoty, H. (Heikki), Ikonen, A. (Anni), Ilonen, J. (Jorma), Jaminki, S. (Sinikka), Jokipuu, S. (Sanna), Karlsson, L. (Leena), Kahonen, M. (Miia), Knip, M. (Mikael), Koivikko, M.-L. (Minna-Liisa), Koreasalo, M. (Mirva), Kytola, J. (Jarita), Latva-aho, T. (Tiina), Lindfors, K. (Katri), Lonnrot, M. (Maria), Mantymaki, E. (Elina), Mattila, M. (Markus), Multasuo, K. (Katja), Mykkanenv, T. (Teija), Niininen, T. (Titha), Niinisto, S. (Sari), Nyblom, M. (Mia), Oikarinen, S. (Sami), Ollikainen, P. (Paula), Pohjola, S. (Sirpa), Rajala, P. (Petra), Rautanen, J. (Jenna), Riikonen, A. (Anne), Romo, M. (Minna), Ruohonen, S. (Suvi), Simell, S. (Satu), Sjoberg, M. (Maija), Stenius, A. (Aino), Tossavainen, P. (Paivi), Vaha-Makila, M. (Mari), Vainionpaa, S. (Sini), Varjonen, E. (Eeva), Veijola, R. (Riitta), Viinikangas, I. (Irene), Schatz, D. (Desmond), Hopkins, D. (Diane), Steed, L. (Leigh), Bryant, J. (Jennifer), Silvis, K. (Katherine), Haller, M. (Michael), Gardiner, M. (Melissa), Mclndoe, R. (Richard), Sharma, A. (Ashok), Anderson, S. W. (Stephen W.), Jacobsen, L. (Laura), Marks, J. (John), Towe, P. D. (P. D.), Ziegler, A. G. (Anette G.), Bonifacio, E. (Ezio), D'Angelo, M. (Miryam), Gavrisan, A. (Anita), Gezginci, C. (Cigdem), Heublein, A. (Anja), Hoffmann, V. (Verena), Hummel, S. (Sandra), Keimer, A. (Andrea), Knopff, A. (Annette), Koch, C. (Charlotte), Koletzko, S. (Sibylle), Ramminger, C. (Claudia), Roth, R. (Roswith), Scholz, M. (Marlon), Stock, J. (Joanna), Warncke, K. (Katharina), Wendel, L. (Lorena), Lernmark, A. (Ake), Ask, M. (Maria), Bremer, J. (Jenny), Cilio, C. (Corrado), Ericson-Hallstrom, E. (Emelie), Fors, A. (Annika), Fransson, L. (Lina), Gard, T. (Thomas), Bennet, R. (Rasmus), Hansen, M. (Monika), Hyberg, S. (Susanne), Jisser, H. (Hanna), Johansen, F. (Fredrik), Jonsdottir, B. (Berglind), Jovic, S. (Silvija), Larsson, H. E. (Helena Elding), Lindstrom, M. (Marielle), Lundgren, M. (Markus), Manson-Martinez, M. (Maria), Markan, M. (Maria), Melin, J. (Jessica), Mestan, Z. (Zeliha), Nilsson, C. (Caroline), Ottosson, K. (Karin), Rahmati, K. (Kobra), Ramelius, A. (Anita), Salami, F. (Falastin), Sjoberg, A. (Anette), Sjoberg, B. (Birgitta), Torn, C. (Carina), Wallin, A. (Anne), Wimar, A. (Asa), Aberg, S. (Sofie), Killian, M. (Michael), Crouch, C. C. (Claire Cowen), Akramoff, A. (Ashley), Chavoshi, M. (Masumeh), Dunson, K. (Kayleen), Hervey, R. (Rachel), Lyons, R. (Rachel), Meyer, A. (Arlene), Mulenga, D. (Denise), Radtke, J. (Jared), Romancik, M. (Matei), Schmitt, D. (Davey), Schwabe, J. (Julie), Zink, S. (Sarah), Becker, D. (Dorothy), Franciscus, M. (Margaret), Smith, M. D. (Maryellen Dalmagro-Elias), Daftary, A. (Ashi), Klein, M. B. (Mary Beth), Yates, C. (Chrystal), Austin-Gonzalez, S. (Sarah), Avendano, M. (Maryouri), Baethke, S. (Sandra), Brown, R. (Rasheedah), Burkhardt, B. (Brant), Butterworth, M. (Martha), Clasen, J. (Joanna), Cuthbertson, D. (David), Eberhard, C. (Christopher), Fiske, S. (Steven), Garmeson, J. (Jennifer), Gowda, V. (Veena), Heyman, K. (Kathleen), Hsiao, B. (Belinda), Karges, C. (Christina), Laras, F. P. (Francisco Perez), Lee, H.-S. (Hye-Seung), Li, Q. (Qian), Liu, S. (Shu), Lynch, K. (Kristian), Maguire, C. (Colleen), Malloy, J. (Jamie), McCarthy, C. (Cristina), Merrell, A. (Aubrie), Meulemans, S. (Steven), Parikh, H. (Hemang), Quigley, R. (Ryan), Remedios, C. (Cassandra), Shaffer, C. (Chris), Smith, L. (Laura), Smith, S. (Susan), Sulman, N. (Noah), Tamura, R. (Roy), Tewey, D. (Dena), Toth, M. (Michael), Vehik, K. (Kendra), Vijayakandipan, P. (Ponni), Wood, K. (Keith), Abbondondolo, M. (Michael), Ballard, L. (Lori), Hadley, D. (David), McLeod, W. (Wendy), Yu, L. (Liping), Miao, D. (Dongmei), Bingley, P. (Polly), Williams, A. (Alistair), Chandler, K. (Kyla), Ball, O. (Olivia), Kelland, I. (Ilana), Grace, S. (Sian), . (), Hagopian, W. (William), Erlich, H. (Henry), Mack, S. J. (Steven J.), Fear, A. L. (Anna Lisa), Ke, S. (Sandra), Mulholland, N. (Niveen), Bourcier, K. (Kasia), Briese, T. (Thomas), Johnson, S. B. (Suzanne Bennett), and Triplett, E. (Eric)

Abstract

Probiotics are linked to positive regulatory effects on the immune system. The aim of the study was to examine the association between the exposure of probiotics via dietary supplements or via infant formula by the age of 1 year and the development of celiac disease autoimmunity (CDA) and celiac disease among a cohort of 6520 genetically susceptible children. Use of probiotics during the first year of life was reported by 1460 children. Time-to-event analysis was used to examine the associations. Overall exposure of probiotics during the first year of life was not associated with either CDA (n = 1212) (HR 1.15; 95%CI 0.99, 1.35; p = 0.07) or celiac disease (n = 455) (HR 1.11; 95%CI 0.86, 1.43; p = 0.43) when adjusting for known risk factors. Intake of probiotic dietary supplements, however, was associated with a slightly increased risk of CDA (HR 1.18; 95%CI 1.00, 1.40; p = 0.043) compared to children who did not get probiotics. It was concluded that the overall exposure of probiotics during the first year of life was not associated with CDA or celiac disease in children at genetic risk.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results